

The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

JUNE 7, 2012

VOL. 366 NO. 23

Delamanid for Multidrug-Resistant Pulmonary Tuberculosis

Maria Tarcela Gler, M.D., Vija Skripconoka, M.D., Epifanio Sanchez-Garavito, M.D., Heping Xiao, M.D., Jose L. Cabrera-Rivero, M.D., Dante E. Vargas-Vasquez, M.D., Mengqiu Gao, M.D., Ph.D., Mohamed Awad, M.B., B.Ch., M.D., Seung-Kyu Park, M.D., Ph.D., Tae Sun Shim, M.D., Ph.D., Gee Young Suh, M.D., Manfred Danilovits, M.D., Hideo Ogata, M.D., Anu Kurve, M.D., Joon Chang, M.D., Ph.D., Katsuhiko Suzuki, M.D., Thelma Tupasi, M.D., Won-Jung Koh, M.D., Barbara Seaworth, M.D., Lawrence J. Geiter, Ph.D., and Charles D. Wells, M.D.

ABSTRACT

BACKGROUND

Delamanid (OPC-67683), a nitro-dihydro-imidazooxazole derivative, is a new anti-tuberculosis medication that inhibits mycolic acid synthesis and has shown potent in vitro and in vivo activity against drug-resistant strains of *Mycobacterium tuberculosis*.

METHODS

In this randomized, placebo-controlled, multinational clinical trial, we assigned 481 patients (nearly all of whom were negative for the human immunodeficiency virus) with pulmonary multidrug-resistant tuberculosis to receive delamanid, at a dose of 100 mg twice daily (161 patients) or 200 mg twice daily (160 patients), or placebo (160 patients) for 2 months in combination with a background drug regimen developed according to World Health Organization guidelines. Sputum cultures were assessed weekly with the use of both liquid broth and solid medium; sputum-culture conversion was defined as a series of five or more consecutive cultures that were negative for growth of *M. tuberculosis*. The primary efficacy end point was the proportion of patients with sputum-culture conversion in liquid broth medium at 2 months.

RESULTS

Among patients who received a background drug regimen plus 100 mg of delamanid twice daily, 45.4% had sputum-culture conversion in liquid broth at 2 months, as compared with 29.6% of patients who received a background drug regimen plus placebo ($P=0.008$). Likewise, as compared with the placebo group, the group that received the background drug regimen plus 200 mg of delamanid twice daily had a higher proportion of patients with sputum-culture conversion (41.9%, $P=0.04$). The findings were similar with assessment of sputum-culture conversion in solid medium. Most adverse events were mild to moderate in severity and were evenly distributed across groups. Although no clinical events due to QT prolongation on electrocardiography were observed, QT prolongation was reported significantly more frequently in the groups that received delamanid.

CONCLUSIONS

Delamanid was associated with an increase in sputum-culture conversion at 2 months among patients with multidrug-resistant tuberculosis. This finding suggests that delamanid could enhance treatment options for multidrug-resistant tuberculosis. (Funded by Otsuka Pharmaceutical Development and Commercialization; ClinicalTrials.gov number, NCT00685360.)

From the Makati Medical Center, Manila (M.T.G.), and the Tropical Disease Foundation, Makati City (M.T.G., T.T.) — both in the Philippines; the State Agency of Tuberculosis and Lung Diseases, Riga, Latvia (V.S.); Hospital Nacional Sergio E. Bernales (E.S.-G.), Unidad de Investigación, Hospital Nacional Daniel A. Carrión (J.L.C.-R.), and Hospital Nacional Hipólito Unanue (D.E.V.-V.) — all in Lima, Peru; Shanghai Pulmonary Hospital, Shanghai (H.X.), and Beijing Chest Hospital, Beijing (M.G.) — both in China; Sadr Abassia Hospital, Cairo (M.A.); National Masan Hospital, Masan (S.-K.P.), Asan Medical Center, Seoul (T.S.S.), Samsung Medical Center, Seoul (G.Y.S., W.-J.K.), and Yonsei University Medical Center, Severance Hospital, Seoul (J.C.) — all in South Korea; Tartu University Lung Hospital, Tartu (M.D.), and North Estonian Medical Center Foundation, Center of Pulmonology, Tallinn (A.K.) — both in Estonia; Fukujiji Hospital, Tokyo (H.O.), and National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka (K.S.) — both in Japan; the University of Texas Health Center at Tyler, Tyler (B.S.); and Otsuka Pharmaceutical Development and Commercialization, Rockville, MD (L.J.G., C.D.W.). Address reprint requests to Dr. Geiter at Otsuka Novel Products/OPDC, 2440 Research Blvd., Rockville, MD 20850, or at lawrence.geiter@otsuka-us.com.

N Engl J Med 2012;366:2151-60.

Copyright © 2012 Massachusetts Medical Society.